Liberal Arts Biotech (300294.SZ): Human vascular hemophilia factor re-approved for clinical trials after process upgrade

Zhitong Finance App News, Liberal Arts Biotech (300294.SZ) issued an announcement. Recently, the company received the “Drug Clinical Trial Approval Notice” (Notice Number: 2026LP02173) for human vascular hemophilia factors approved and issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”). This approval was approved for a new declaration after completing the core production process upgrade for this product. This is not a new initial declaration.

The current human vascular hemophilia factor process was re-approved for clinical trials. This is an important optimization of the company's core production technology for this product and lays a solid foundation for the smooth progress of clinical trials. The approved clinical trial project will further stimulate the R&D team's enthusiasm for innovation, improve the company's product pipeline layout in the field of rare hemorrhagic diseases, and provide strong support for enriching the blood products product line and strengthening core market competitiveness.